Literature DB >> 21801324

Clinical and functional prediction of moderate to severe obstructive sleep apnoea.

Caterina Bucca1, Luisa Brussino, Milena Maria Maule, Ileana Baldi, Giuseppe Guida, Beatrice Culla, Franco Merletti, Antonio Foresi, Giovanni Rolla, Roberto Mutani, Alessandro Cicolin.   

Abstract

INTRODUCTION: Upper airway inflammation and narrowing are characteristics of obstructive sleep apnoea (OSA). Inflammatory markers have been found to be increased in exhaled breath and induced sputum of patients with OSA.
OBJECTIVES: The aim of this study was to investigate if the measurement of exhaled nitric oxide (F(ENO) ), as marker of airway inflammation, together with the forced mid-expiratory/mid-inspiratory airflow ratio (FEF(50) /FIF(50) ), as marker of upper airway narrowing, may help to predict OSA.
METHODS: Two hundred one consecutive outpatients with suspected OSA were prospectively studied between January 2004 and December 2005. All patients underwent clinical examination, spirometry with measurement of FEF(50) /FIF(50) , maximum inspiratory pressure, arterial blood gas analysis, exhaled nitric oxide (F(ENO) ) and overnight polysomnography. Linear regression models were used to evaluate the effect of measured variables on the apnoea-hypopnoea index (AHI). Models were cross-validated by bootstrapping.
RESULTS: Most of the patients were obese and had severe OSA. FEF(50) /FIF(50) , F(ENO) and an interaction term between smoking and F(ENO) contributed significantly to the predictive model for AHI, in addition to age, neck circumference, body mass index and carboxyhaemoglobin saturation. A nomogram to predict AHI was obtained, which converted the effect of each covariate in the model to a 0-100 scale. The nomogram showed a good predictive ability for AHI values between 25 and 64.
CONCLUSIONS: The measurement of F(ENO) and of FEF(50) /FIF(50) improves the ability to predict OSA and may be used to identify patients who require a sleep study.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21801324     DOI: 10.1111/j.1752-699X.2010.00223.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  7 in total

1.  The prevalence and associated risk factors of sleep disorder-related symptoms in pregnant women in China.

Authors:  Xiao-Hong Cai; Yu-Peng Xie; Xiu-Cui Li; Wang-Lei Qu; Ting Li; Hong-Xia Wang; Jie-Qiang Lv; Liang-Xing Wang
Journal:  Sleep Breath       Date:  2012-11-07       Impact factor: 2.816

2.  A clinical prediction formula for apnea-hypopnea index.

Authors:  Mustafa Sahin; Cem Bilgen; M Sezai Tasbakan; Rasit Midilli; Ozen K Basoglu
Journal:  Int J Otolaryngol       Date:  2014-10-01

Review 3.  Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research.

Authors:  Stefania Nicola; Giovanni Rolla; Luisa Brussino
Journal:  Drugs Context       Date:  2019-10-02

4.  Th1- and Th17-Related Cytokines in Venous and Arterial Blood of Sclerodermic Patients with and without Digital Ulcers.

Authors:  S Nicola; M Fornero; E Fusaro; C Peroni; M Priora; G Rolla; C Bucca; L Brussino
Journal:  Biomed Res Int       Date:  2019-10-07       Impact factor: 3.411

5.  Development and validation of a nomogram for predicting the risk of obstructive sleep apnea in patients with type 2 diabetes.

Authors:  Huan Shi; Shoukui Xiang; Xiaolin Huang; Long Wang; Fei Hua; Xiaohong Jiang
Journal:  Ann Transl Med       Date:  2020-12

6.  Development and Comparison of Predictive Models Based on Different Types of Influencing Factors to Select the Best One for the Prediction of OSAHS Prevalence.

Authors:  Xin Fan; Mu He; Chang Tong; Xiyi Nie; Yun Zhong; Min Lu
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435

Review 7.  Enabling Early Obstructive Sleep Apnea Diagnosis With Machine Learning: Systematic Review.

Authors:  Daniela Ferreira-Santos; Pedro Amorim; Tiago Silva Martins; Matilde Monteiro-Soares; Pedro Pereira Rodrigues
Journal:  J Med Internet Res       Date:  2022-09-30       Impact factor: 7.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.